FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:IQGAP2-ATRNL1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: IQGAP2-ATRNL1
FusionPDB ID: 40180
FusionGDB2.0 ID: 40180
HgeneTgene
Gene symbol

IQGAP2

ATRNL1

Gene ID

10788

26033

Gene nameIQ motif containing GTPase activating protein 2attractin like 1
Synonyms-ALP|bA338L11.1|bA454H24.1
Cytomap

5q13.3

10q25.3

Type of geneprotein-codingprotein-coding
Descriptionras GTPase-activating-like protein IQGAP2attractin-like protein 1
Modification date2020031320200313
UniProtAcc

Q13576

Main function of 5'-partner protein: FUNCTION: Binds to activated CDC42 and RAC1 but does not seem to stimulate their GTPase activity. Associates with calmodulin.

Q5VV63

Main function of 5'-partner protein: FUNCTION: May play a role in melanocortin signaling pathways that regulate energy homeostasis. {ECO:0000250}.
Ensembl transtripts involved in fusion geneENST idsENST00000274364, ENST00000379730, 
ENST00000396234, ENST00000502745, 
ENST00000508410, 		ENST00000527407, 
ENST00000529665, ENST00000303745, 
ENST00000355044, ENST00000423111, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 6 X 3=1269 X 7 X 5=315
# samples 79
** MAII scorelog2(7/126*10)=-0.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(9/315*10)=-1.8073549220576
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: IQGAP2 [Title/Abstract] AND ATRNL1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: IQGAP2 [Title/Abstract] AND ATRNL1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)IQGAP2(75866482)-ATRNL1(117278773), # samples:1
Anticipated loss of major functional domain due to fusion event.IQGAP2-ATRNL1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
IQGAP2-ATRNL1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneIQGAP2

GO:0034314

Arp2/3 complex-mediated actin nucleation

12515716

HgeneIQGAP2

GO:0070493

thrombin-activated receptor signaling pathway

12515716



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:75866482/chr10:117278773)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across IQGAP2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ATRNL1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000274364IQGAP2chr575866482-ENST00000355044ATRNL1chr10117278773+53776782371163308
ENST00000274364IQGAP2chr575866482-ENST00000423111ATRNL1chr10117278773+14206782371163308
ENST00000274364IQGAP2chr575866482-ENST00000303745ATRNL1chr10117278773+15716782371163308

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000274364ENST00000355044IQGAP2chr575866482-ATRNL1chr10117278773+0.0012530730.9987469
ENST00000274364ENST00000423111IQGAP2chr575866482-ATRNL1chr10117278773+0.0061617020.99383825
ENST00000274364ENST00000303745IQGAP2chr575866482-ATRNL1chr10117278773+0.0039951760.9960049

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for IQGAP2-ATRNL1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
IQGAP2chr575866482ATRNL1chr10117278773678147QWLRAMESIGLPKIAFSQHNTIMDLV

Top

Potential FusionNeoAntigen Information of IQGAP2-ATRNL1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
IQGAP2-ATRNL1_75866482_117278773.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B13:01MESIGLPKI0.99810.7723514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B44:03MESIGLPKI0.9940.7356514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B41:01MESIGLPKI0.47520.8025514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B39:13MESIGLPKI0.32070.6912514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B52:01MESIGLPKI0.09860.742514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B45:01MESIGLPKIA0.9930.5565515
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B50:01MESIGLPKIA0.89790.6111515
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B51:07MESIGLPKI0.05810.6941514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B40:06MESIGLPKIA0.99120.531515
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B44:26MESIGLPKI0.9940.7356514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B44:07MESIGLPKI0.9940.7356514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B44:13MESIGLPKI0.9940.7356514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B39:02MESIGLPKI0.24770.6891514
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-A25:01ESIGLPKIAF0.99570.5837616
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B50:04MESIGLPKIA0.89790.6111515
IQGAP2-ATRNL1chr575866482chr10117278773678HLA-B50:05MESIGLPKIA0.89790.6111515

Top

Potential FusionNeoAntigen Information of IQGAP2-ATRNL1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
IQGAP2-ATRNL1_75866482_117278773.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-0906GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1117GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1117LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1152GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1152LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1401GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1401LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1401IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1401PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1404GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1404LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1404IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1404PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1405GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1405LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1407GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1407LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1408GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1408LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1411GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1411LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1414GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1418GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1423GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1423LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1426GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1426LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1426IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1426PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1428GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1428LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1428IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1428PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1431GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1431LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1432GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1432LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1435GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1435LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1436GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1438GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1438LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1438IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1438PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1439GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1439LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1439IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1439PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1443GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1443LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1444GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1445GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1445LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1448GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1450GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1450LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1450IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1450PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1454GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1454LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1454IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1454PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1455GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1455LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1456GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1456LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1458GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1458LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1458IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1458PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1459GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1459LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1460GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1460LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1460IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1460PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1461GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1461LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1461IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1461PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1462GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1462LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1464GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1468GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1468LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1468IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1470GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1470LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1471GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1471LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1471IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1471PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1472GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1475GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1475LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1475IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1475PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1482GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1482LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1482IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1482PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1486GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1486LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1486IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1486PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1487GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1487LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1487IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1487PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1488GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1488LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1488IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1488PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1490GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1490LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1490IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1490PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1491GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1491LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1493GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1493LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1493IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1495GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1495LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1496GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1496LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1497GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1497LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1497IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1497PKIAFSQHNTIMDLV1126
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1499GLPKIAFSQHNTIMD924
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1499LPKIAFSQHNTIMDL1025
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1499IGLPKIAFSQHNTIM823
IQGAP2-ATRNL1chr575866482chr10117278773678DRB1-1499PKIAFSQHNTIMDLV1126

Top

Fusion breakpoint peptide structures of IQGAP2-ATRNL1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2129ESIGLPKIAFSQHNIQGAP2ATRNL1chr575866482chr10117278773678

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of IQGAP2-ATRNL1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2129ESIGLPKIAFSQHN-7.15543-7.26883
HLA-B14:023BVN2129ESIGLPKIAFSQHN-4.77435-5.80965
HLA-B52:013W392129ESIGLPKIAFSQHN-6.80875-6.92215
HLA-B52:013W392129ESIGLPKIAFSQHN-4.20386-5.23916
HLA-A11:014UQ22129ESIGLPKIAFSQHN-7.5194-8.5547
HLA-A11:014UQ22129ESIGLPKIAFSQHN-6.9601-7.0735
HLA-A24:025HGA2129ESIGLPKIAFSQHN-7.52403-7.63743
HLA-A24:025HGA2129ESIGLPKIAFSQHN-5.82433-6.85963
HLA-B27:056PYJ2129ESIGLPKIAFSQHN-3.28285-4.31815
HLA-B44:053DX82129ESIGLPKIAFSQHN-5.91172-6.94702
HLA-B44:053DX82129ESIGLPKIAFSQHN-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of IQGAP2-ATRNL1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
IQGAP2-ATRNL1chr575866482chr10117278773514MESIGLPKIATGGAGTCTATTGGTCTACCCAAGATT
IQGAP2-ATRNL1chr575866482chr10117278773515MESIGLPKIAATGGAGTCTATTGGTCTACCCAAGATTGCA
IQGAP2-ATRNL1chr575866482chr10117278773616ESIGLPKIAFGAGTCTATTGGTCTACCCAAGATTGCATTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
IQGAP2-ATRNL1chr575866482chr101172787731025LPKIAFSQHNTIMDLCTACCCAAGATTGCATTCTCACAACACAATACAATCATGGACCTT
IQGAP2-ATRNL1chr575866482chr101172787731126PKIAFSQHNTIMDLVCCCAAGATTGCATTCTCACAACACAATACAATCATGGACCTTGTG
IQGAP2-ATRNL1chr575866482chr10117278773823IGLPKIAFSQHNTIMATTGGTCTACCCAAGATTGCATTCTCACAACACAATACAATCATG
IQGAP2-ATRNL1chr575866482chr10117278773924GLPKIAFSQHNTIMDGGTCTACCCAAGATTGCATTCTCACAACACAATACAATCATGGAC

Top

Information of the samples that have these potential fusion neoantigens of IQGAP2-ATRNL1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
HNSCIQGAP2-ATRNL1chr575866482ENST00000274364chr10117278773ENST00000303745TCGA-CV-7243-01A

Top

Potential target of CAR-T therapy development for IQGAP2-ATRNL1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneATRNL1chr5:75866482chr10:117278773ENST0000035504423291231_125101380.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to IQGAP2-ATRNL1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to IQGAP2-ATRNL1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource